Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252493 · ClinicalTrials.gov registry record
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
A clinical trial of Crohn Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06252493 is a study of Crohn Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06252493, a study of Crohn Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the collagen-binding radiotracer will be performed. The study aims to establish the performance figures of PET/MR using \[68Ga\]CBP8-PET for preoperative detection and differentiation of strictures with a fibrotic component in patients with Crohn's disease by using surgical and histologic findings (when available) as the standard for comparison. Furthermore, the investigators will determine the performance figures with which strictures are identified and characterized by PET/MR using \[68Ga\]CBP8-PET compared to each modality in isolation (PET alone or MR alone). Blood and tissue markers for fibrostenosis will be explored (either predictive or as biomarkers for fibrotic burden), using histologic and molecular testing by using surgical and histologic findings (when available) as the standard for comparison. Lastly the investigators want to determine the performance figures with which strictures are identified and characterized by PET/MR using \[68Ga\]CBP8-PET compared to each modality in isolation (PET alone or MR alone).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood Draw
- DRUG Radiotracer Injection
- DIAGNOSTIC_TEST Imaging
- DRUG Contrast Media, Magnetic Resonance
- DRUG Glucagon
Study Locations (1)
Massachusetts
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-12-19 |
| Est. Completion | 2029-12-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06252493
The ClinicalTrials.gov registry entry for NCT06252493 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 5 interventions - of which Blood Draw is the first listed.
NCT06252493 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06252493 about?
NCT06252493 is a clinical study titled "Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.". In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the collagen-binding radiotracer will be performed. The study aims to establish the performance figures of PET/MR using \[68Ga\]CBP8-PET ...
What is the current status of trial NCT06252493?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2023-12-19. Estimated completion is 2029-12-19.
What conditions does trial NCT06252493 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT06252493?
The interventions under investigation include: Blood Draw (DIAGNOSTIC_TEST), Radiotracer Injection (DRUG), Imaging (DIAGNOSTIC_TEST), Contrast Media, Magnetic Resonance (DRUG), Glucagon (DRUG).
Who is sponsoring clinical trial NCT06252493?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252493 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.